short stature
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Bone age >=14 years in boys and 13 years in girls; (2) Height less than or equal to -2.0SDS compared to same sex and age; (3) Growth velocity = 10th percentile of the same sex and gestational age; (7) The thyroid function is normal, including blood free thyroxine (FT4), free triiodothyronine (FT3) and thyroid-stimulating hormone (TSH) levels within the normal reference value range; (8) The karyotype of the chromosome is normal, 46,XX (only female whose height iless than or equal to -2.0SDS compared to same sex and age); (9) Patients who have not received rhGH treatment, GnRHa, aromatase analogs and other drugs in the past 2 years; (10) Children with no contraindications to rhGH treatment evaluated by a doctor;=
Exclusion criteria
Exclusion criteria: (1) Patients with liver and kidney dysfunction (ALT>2 times the upper limit of normal value, Cr>upper limit of normal value); (2) Patients with active hepatitis B; (3) Patients with severe heart and lung, blood system, malignant tumors, diabetes and other diseases or systemic infections, and immunocompromised patients; (4) Diagnosed with other types of growth and development abnormalities, such as growth hormone deficiency, polypituitary hormone deficiency, Turner syndrome, Noonan syndrome, Laron syndrome, growth hormone receptor deficiency, small for gestational age with short stature, Growth retardation caused by malnutrition, growth retardation caused by hypothyroidism, etc., girls with lagging growth did not rule out chromosomal abnormalities; (5) Children with microcephaly or with intelligence or developmental retardation or with abnormal skeletal development or with other congenital malformations; (6) Growth rate <0.5cm in the past 3 months; (7) Those who are known to be highly allergic or allergic to the test drug in this study; (8) Participants in clinical trials of other drugs related to growth and development within 3 months; (9) The investigator believes that the patient is not suitable for other situations in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| height;CV;PAH;HtSDSBA;bone age;knee score; | — |
Countries
China
Contacts
Public ContactWang Chun-Lin
The First Affiliated Hospital of Zhejiang University
Outcome results
None listed